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SUMMARY 4 
Variables associated with recurrent Dupuytren’s disease, or a ‘diathesis’, have been 5 
investigated, but those associated with functional outcome and complications are 6 
less well studied. 7 
Outcomes 1 or 5 years after an aponeurotomy, fasciectomy or dermofasciectomy 8 
were assessed by patient interview and examination at five UK centres.  Four 9 
hundred and thirty two procedures were studied.   10 
The reoperation rate did not differ at 1 year (p=0.396, Chi-square test with Monte 11 
Carlo simulation), but was higher after aponeurotomy in the 5-year group (30%, 12 
versus 6% after fasciectomy and 0% after dermofasciectomy, p=0.003, Chi square 13 
test with Monte Carlo simulation).  14 
Loss of function (DASH>15) did not differ between procedures at 5 years, even when 15 
reoperation and other variables were controlled.  Diabetes, female gender and 16 
previous ipsilateral surgery were associated with poorer function in logistic 17 
regression analysis. 18 
The variables associated with poor function after treatments differ from diathesis 19 
variables.  Aponeurotomy had lower complication rates than fasciectomy and 20 
dermofasciectomy.  This may counterbalance the former’s higher recurrence rate 21 
and explain why aponeurotomy demonstrated similar long-term functional outcome 22 
compared to excisional surgery in this study. 23 
 24 
Level of evidence: III 25 
26 
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INTRODUCTION 28 
The factors associated with a ‘Dupuytren’s diathesis’, or tendency for disease 29 
recurrence or extension, have been studied (Abe et al., 2004, Dias et al., 2013, 30 
Hindocha et al., 2006, van Rijssen et al., 2012).  However the objective outcomes 31 
studied, such as recurrence, provide an incomplete representation of the diverse 32 
disability and functional impairment experienced by patients with Dupuytren’s 33 
disease (Rodrigues et al., 2014).  Recurrence and extension are not the only causes 34 
of poor outcome after surgery for Dupuytren’s disease.  For example, complications 35 
causing loss of finger flexion may also have serious functional consequences.  In 36 
addition failure to fully straighten a finger with treatment may not adversely affect 37 
outcome.  This is outcome measures such as the Disabilities of the Arm, Shoulder 38 
and Hand (DASH) patient-reported outcome measure (PROM) and the Sollerman 39 
hand score correlate poorly with angular deformity (Degreef et al., 2009, Engstrand 40 
et al., 2009, Jerosch-Herold et al., 2011, Sinha et al., 2002, Zyluk and Jagielski, 41 
2007).  However, a new Dupuytren’s disease-specific PROM, the Unité 42 
Rhumatologique des Affections de la Main (URAM) scale correlates with angular 43 
deformity (Beaudreuil et al., 2011). 44 
A recent review has considered the reported rates of complications following 45 
treatment of Dupuytren’s disease (Crean et al., 2011), but factors associated with 46 
poor functional outcome and complications of surgery have not been investigated.  47 
Such factors may not be captured by all outcome measures, for example the URAM 48 
does not evaluate pain and concentrates on assessing activities that require finger 49 
extension, rather than flexion (Beaudreuil et al., 2014). 50 
This study assessed the functional outcomes and adverse outcomes of surgery for 51 
Dupuytren’s disease and the factors associated with them, rather than those 52 
associated with recurrence or extension alone. 53 
54 
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METHODS 55 
Patient recruitment and data collection 56 
This project was independently approved as service evaluation at each participating 57 
centre.  Information governance and, when required, Caldicott Guardian approval 58 
were also obtained locally.  Clinical coding departments at five UK NHS hand surgery 59 
centres (Derby, Livingston, Nottingham, Plymouth, Rotherham) identified patients 60 
who had undergone aponeurotomy, fasciectomy or dermofasciectomy either 1 year 61 
or 5 years earlier.  Patients living within 20 miles of the centre were invited to attend 62 
a locally approved service evaluation.  A single surgeon (JR) assessed all patients 63 
who could be assessed 1 or 5 years (+/- 2 months) after their surgery.  A 64 
standardised history and examination was performed on all patients. 65 
Data collected included patient demographics, known and suggested risk factors for 66 
the progression of Dupuytren’s disease, complications of surgery, reoperation to the 67 
same digit since the index procedure, angular deformity and the DASH PROM. 68 
If more than one digit on a hand had been treated with the same procedure (e.g. 69 
fasciectomy to the ring and little fingers in a single procedure), then only one digit 70 
was assessed.  The digit selected in such cases was the digit with the worst total 71 
active extension deficit. 72 
If different procedures were performed in one operation (e.g. fasciectomy to the ring 73 
finger and dermofasciectomy to the little finger), then both procedures were analysed 74 
as separate events for the study of objective outcomes, but the patient was not 75 
included in the analyses of functional outcome. 76 
If both hands were treated with the same procedure in one operation (this only 77 
occurred with aponeurotomy) then only the treated digit on the dominant hand was 78 
assessed; this was included in the analyses of both the objective and functional 79 
outcomes.  This avoided any patient being recruited to the same subgroup more than 80 
once (Sauerland et al., 2003). 81 
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We chose to assess three main types of variables: functional outcome, which was 82 
the focus of the study; objective outcomes, i.e. researcher-defined measures of the 83 
complications of treatment; and patient variables, i.e. non-surgical factors that might 84 
affect outcomes such as comorbidities.  Thus, we would be able to compare the 85 
functional outcomes of different procedures, with objective outcomes (such as 86 
reoperation) and control for other variables such as comorbidities. 87 
 88 
Objective outcome measurement 89 
Reoperation (defined as further surgery for recurrence or extension of Dupuytren’s 90 
disease in the same digit) was assessed by patient recall and confirmed via hospital 91 
records if unclear.  The same single observer (JR) assessed passive extension 92 
deficit at the metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) 93 
joints for all cases.  During all measurements, the other joints in the same finger 94 
being assessed were held in maximum passive flexion, to standardise the effect of 95 
dynamism (Rodrigues et al., 2014). 96 
Functional outcome 97 
Proportions of patients with poor functional outcome 1 and 5 years after the three 98 
different types of procedure (aponeurotomy, fasciectomy or dermofasciectomy) were 99 
compared.  100 
Functional outcome was based on the DASH (DASH≥15 considered “poor”, 101 
DASH<15 considered “good” (Kennedy et al., 2011)).  As the operation groups were 102 
not matched, it was necessary to control for differences between the groups that 103 
might influence the comparison of functional outcome using logistic regression.   104 
Adverse outcomes 105 
The adverse outcomes assessed were: 106 
 cold intolerance (described using an existing scale (Campbell and Kay, 107 
1998)) 108 
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 loss of flexion (defined as a fingertip pulp to distal palmar crease distance 109 
over 10mm on active flexion) 110 
 infection (defined as patient recall of the need for at least one postoperative 111 
course of antibiotics that was not prescribed as prophylaxis) 112 
 complex regional pain syndrome (CRPS) (defined using the modified 113 
International Association for the Study of Pain (IASP) criteria based on 114 
examination and patient recall (Harden et al., 2007)) 115 
 altered sensation (defined as failure to identify 2/3 tests of two point 116 
discrimination at 6 millimetres over the pulp of the operated digit in the 117 
territory of either digital nerve) 118 
Sample size 119 
A sample size with ten outcome events per predictor variable is often quoted for 120 
logistic regression analyses.  As we used twelve predictor variables were used, this 121 
would require 120 poor functional outcomes (DASH>15) in our study.  However, 122 
more recent examination of this rule has suggested that five to nine outcome events 123 
per predictor variable may be acceptable (Vittinghoff and McCulloch, 2007), in which 124 
case 60-108 poor functional outcomes would be needed.  As the proportion of 125 
patients with poor functional outcome following Dupuytren’s disease surgery is not 126 
well described, it was assumed that approximately 25% of treatments would result in 127 
poor functional outcomes.  On this basis, a total target of 400 was required to 128 
achieve a target of 100 poor functional outcomes. 129 
Statistical analysis 130 
Analyses were performed using Prism 6.0 for Mac OS X (GraphPad® Software, 131 
2012) and SPSS® Statistics version 21 (IBM® Software, 2012).  DASH scores were 132 
dichotomised into those above 15 (symptomatic scores) and those below 15 133 
(asymptomatic scores), based on guidance from the developer of the DASH 134 
(Kennedy et al., 2011). 135 
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The suitability of the data for logistic regression was verified prior to analysis.  In 136 
particular, the data was examined for the absence of multicollinearity, which occurs 137 
when two or more of the independent variables studied correlate with each other very 138 
strongly.  If present, this can affect regression (Pallant, 2010).  To do this tolerance, 139 
the amount of variance that cannot be accounted for by other variables, was 140 
calculated for each variable.  If it is low, then the variable may show collinearity with 141 
another variable, or multicollinearity with several variables (Pallant, 2010).  In 142 
keeping with convention, an unacceptable level of tolerance was defined as <0.1. 143 
Binary logistic regression analysis was performed to identify and control for 144 
independent variables associated with impaired function defined as DASH>15 at 1 145 
year after treatment (this is the threshold at which the developers of the DASH score 146 
consider that a score becomes symptomatic (Kennedy et al., 2011)) and with 147 
adverse outcomes.  The operation type was entered with aponeurotomy as the 148 
constant with fasciectomy and dermofasciectomy compared to it. 149 
The independent variables that were hypothesised to affect functional outcome were 150 
controlled in these comparisons with the aim of achieving a more accurate 151 
comparison of true functional outcome.  The variables were: further ipsilateral 152 
Dupuytren’s disease surgery since the index procedure (based on patient report, 153 
scar examination and clinical note verification when possible; termed “surgery 154 
since”), the length of follow up (1 year or 5 years) and eight others, some of which 155 
are part of the traditional Dupuytren’s diathesis, and others are factors that might be 156 
expected to influence functional outcome: 157 
 Self reported alcohol consumption >28 United Kingdom units per week 158 
(where 1 unit is 10 milligrams ethanol) 159 
 Active smoker 160 
 Self reported positive family history of Dupuytren’s disease 161 
 Surgery to the little finger 162 
 7 
 The presence of knuckle pads on examination 163 
 The index procedure was revision of previous surgery (defined as previous 164 
surgery to the same digit) 165 
 Diabetes mellitus 166 
 Gender 167 
Some of these are part of the traditional Dupuytren’s diathesis, whilst the others are 168 
factors that might be expected to influence functional outcome. 169 
A similar approach was used to study adverse events.  Proportions of patients with 170 
each adverse outcome were compared between the three treatments 171 
(aponeurotomy, fasciectomy and dermofasciectomy) with Chi square tests.  172 
Hierarchical binary logistic regression analyses were performed for each adverse 173 
outcome in a similar manner as for functional outcome.  The independent variables 174 
selected for study were ones that might influence the risk of complications.  In 175 
addition to further ipsilateral surgery for Dupuytren’s disease, they were: 176 
 Multiple digit surgery during index procedure 177 
 Gender 178 
 Diabetes mellitus 179 
 Smoking status 180 
 Index procedure was revision of previous surgery (defined as previous 181 
surgery to the same digit) 182 
For adverse outcomes expected to change between 1 and 5 years postoperatively, 183 
the time point (1 year versus 5 years) was also studied.  These were loss of flexion 184 
and cold intolerance (which might improve in the intervening period).  For other 185 
adverse outcomes, the 1 year and 5 year assessments were studied together. 186 
Loss of flexion was studied as an ‘adverse outcome’ that might result from hand 187 
surgery, even in Dupuytren’s disease, where the goal of surgery tends to relate to 188 
finger extension. 189 
 8 
To control for false discoveries (false positives), the p value threshold considered 190 
significant was adjusted using a described method (Benjamini and Hochberg, 1995).  191 
As the variables associated with poor functional outcome have not been studied 192 
widely, a false discovery rate (Q) of 20% was considered reasonable to minimise the 193 
risk of a type 2 error.  The variables in the model were ordered by p value and 194 
ranked and the threshold for each variable calculated using the formula (i/m)*Q, 195 
where ‘i’ was the rank of the variable and ‘m’ was the total number of tests (13 in the 196 
analysis of functional outcome).  If the p value obtained was smaller than 0.05 and 197 
also lower than its calculated threshold, then the result was considered significant. 198 
 199 
RESULTS 200 
Patients and procedures 201 
We recruited and assessed 414 patients between September 2011 and June 2013 202 
across all sites.  They had undergone 433 procedures.  One had undergone an 203 
amputation after the index procedure and was excluded from the analysis. 204 
All remaining 432 procedures in 413 patients were included in analyses of 205 
reoperation and complications, as these were recorded at digit level (see Table 1).  206 
However, function is assessed at patient level; only the dominant hands were 207 
assessed for ten of the 413 patients, who had undergone aponeurotomy to both 208 
hands in a single procedure.  A further nine patients had undergone different 209 
procedures to different digits and so were excluded from analyses of function.  Thus, 210 
404 patients were included in analyses of function (see Table 1). 211 
Nine patients (2%) had two different procedures.  This comprised seven patients in 212 
the 1-year postop group who had undergone fasciectomy to a digit and 213 
dermofasciectomy to a different digit of the same hand and one patient in the 5-year 214 
postop group.  The other patient had undergone fasciectomy to one hand and 215 
aponeurotomy to the other hand in the same procedure. 216 
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The demographics of the 413 patients are shown in Table 2.  There were 217 
reoperations following 11 aponeurotomies and 11 fasciectomies but none following 218 
dermofasciectomy.  Following aponeurotomy there were 4/11 further aponeurotomies 219 
and 7/11 fasciectomies.  Following fasciectomy, there was one aponeurotomy, 5/11 220 
fasciectomies and 5/11 dermofasciectomies.  These proportions were significantly 221 
different (p=0.041 (99% confidence intervals: 0.036, 0.046), Chi square test with 222 
Monte Carlo simulation (10 000 replicates)).  It was not clear whether these choices 223 
were due to patient preference, surgeon preference or other reasons. 224 
Objective outcomes 225 
The percentage of procedures that had undergone reoperation was not different 226 
between the three procedures at 1 year (p=0.396, Chi square test using Monte Carlo 227 
method, see Table 3).  However, the reoperation rate was significantly greater after 228 
aponeurotomy at 5 years (p=0.000, Chi square test, see Table 3).  The reoperation 229 
rate after aponeurotomy was significantly higher at 5 years than at one year (6/20 230 
versus 5/114, p=0.002, Fisher’s Exact test).  The reoperation rate did not change 231 
between 1 and 5 years for fasciectomy (3/126 versus 8/125).  There were no 232 
reoperations following dermofasciectomy. 233 
We assessed a sub-group of ‘poor objective outcomes’ (which we defined as patients 234 
who had undergone reoperation or had not undergone reoperation but had either 235 
MCP joint or PIP joint fixed flexion contractures >25o) to account for patients who 236 
may have declined revision surgery or been considered unsuitable for further 237 
surgery.  This group comprised those who had undergone reoperation and those 238 
who had considerable loss of extension but had not undergone further surgery.  The 239 
proportion of ‘poor objective outcomes’ was significantly greater 1 year after more 240 
invasive procedures (see Table 3).  However, there was no difference between 241 
procedures at 5 years. 242 
Functional outcome  243 
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Overall 96/404 (24%) had poor functional outcomes.  The proportion of patients with 244 
symptomatic DASH scores (DASH>15) was not significantly different between the 245 
three procedures either at 1 or 5 years (Table 4).  However different proportions of 246 
these patients had undergone further surgery over the 1 or 5 years, with a 247 
significantly higher reoperation rate 5 years after aponeurotomy than after 248 
dermofasciectomy. 249 
As the prerequisites were met in terms of tolerance of the variables studied, logistic 250 
regression analysis was performed.  The omnibus test demonstrates whether the 251 
model built by the analysis performs well in terms of ‘goodness of fit’, i.e. whether the 252 
included variables do contribute to predicting poor functional outcome.  Here, it was 253 
statistically significant (p<0.001), demonstrating that this was the case.  The results 254 
of the logistic regression analysis are shown in Table 5.  Controlling for confounding 255 
variables such as the effect of further surgery and length of follow up, the only other 256 
variables that showed significant associations with poor function were female gender, 257 
diabetes mellitus and previous ipsilateral surgery for Dupuytren’s disease.  The 258 
variables considered part of the classical Dupuytren’s diathesis were not associated 259 
with a poor functional outcome. 260 
Adverse outcomes 261 
The rates of different adverse outcomes are shown in Table 6, grouped by procedure 262 
(and length of follow up where relevant).  Complications that were hypothesised to 263 
improve over time (cold intolerance and loss of flexion) were more common at 1 than 264 
at 5 years.  Infection and altered sensation were observed more frequently after 265 
more invasive procedures than after aponeurotomy.  At 1 year cold intolerance and 266 
loss of flexion were more common after more invasive procedures.  There was no 267 
difference between procedures at 5 years, although significantly more of the 268 
aponeurotomy group had undergone further surgery (p=0.002). 269 
Tolerances for all variables studied in relation to complications were acceptable, and 270 
logistic regression analyses were performed for all complications except CRPS, as 271 
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this was found infrequently.  Each of the models for cold intolerance, loss of flexion, 272 
altered sensation and infection was significant on omnibus testing, which confirms 273 
that each of the regression models performed well relative to the baseline data 274 
without the independent variables controlled.  All statistically significant results from 275 
the analyses are shown in Table 7. 276 
277 
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 278 
DISCUSSION 279 
Objective outcomes 280 
This study confirms that aponeurotomy has a higher reoperation than fasciectomy or 281 
dermofasciectomy.  The cross-sectional design of our study means that patients’ 282 
immediate preoperative condition and postoperative outcome are not known, which 283 
limits the interpretation of our data in Table 3.  In particular, it is possible that the 284 
patients in this study who underwent more invasive procedures had presented with 285 
more severe preoperative disease and not achieved full correction at surgery.  This 286 
might explain why more of them had ‘poor objective outcomes’ at 1 year here.  287 
However, reliable rates of initial correction have been demonstrated, including for 288 
aponeurotomy (Pess et al., 2012). 289 
Reoperation may be an important clinical and economic endpoint to study, but is a 290 
complex variable.  In order to undergo further treatment, a patient would have to 291 
have recurrent or extended disease that is amenable to further surgery, be offered 292 
surgery by a clinician and consent to the further treatment.  Some of our study group 293 
described progressive recurrence but had not sought further intervention.  This 294 
pattern has been previously reported, with ‘reoperation rates’ lower than ‘treatment 295 
failure’ rates (van Rijssen et al., 2012).  As a result, reoperation is not an accurate or 296 
valid surrogate for recurrence.  In this study, the proportions of patients undergoing 297 
reoperation within 5 years of treatment were higher after aponeurotomy, as might be 298 
expected, but were still lower than reported by others (Foucher et al., 2003; van 299 
Rijssen et al., 2012).  One randomised controlled trial reported a reoperation rate 300 
within 5 years of 33/52 (63%) for aponeurotomy and 4/41 (9%) for fasciectomy (van 301 
Rijssen et al., 2012).  Whereas their reoperation rate for aponeurotomy was two 302 
times greater than that in our study, their reoperation rate after fasciectomy was 303 
similar to ours (6%) 304 
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Abe and colleagues investigated the factors associated with reoperation at a mean 305 
follow-up of 5 years in a small Japanese population (Abe et al., 2004).  They found 306 
that the factors in the classical diathesis had prognostic value.  However, the 307 
applicability of their findings to other populations is not clear.  Additionally, the length 308 
of follow-up ranged from 3 to 12 years.  As Dupuytren’s disease is a slowly 309 
progressive condition, patients 3 years following Dupuytren’s disease surgery are not 310 
comparable to those 12 years after treatment. 311 
Hindocha (2006) studied the factors associated with recurrence of palpable disease 312 
in the operated field (Hindocha et al., 2006).  They identified that male gender and 313 
young age of onset were associated with recurrence of palpable disease.  Whilst this 314 
is a common definition of recurrence (Becker and Davis, 2010), it is not clinically 315 
relevant.  The reappearance of palpable disease alone does not require treatment, 316 
as supported by comparing the proportion of patients who have poor objective 317 
outcome to those who have undergone reoperation (Table 3 here).  In addition 318 
reappearance of palpable disease does not necessarily impair function. 319 
van Rijssen et al. (2012) studied factors associated with recurrence defined as a 320 
progressive angular deformity.  They concluded that the scoring system proposed by 321 
Abe et al  (2004) did not predict recurrence.  As further treatment might become 322 
advisable with deterioration in angular deformity, this may be a more clinically 323 
applicable and reliable endpoint than those used in either of the earlier studies by 324 
Abe et al. and Hindocha et al.  However, it does not describe the patient’s hand 325 
function or health-related quality of life, which is probably also influenced by factors 326 
such as complications. 327 
Most recently, Dias (2013) investigated factors associated with contracture 328 
recurrence in a randomised controlled trial of firebreak dermofasciectomy versus z-329 
plasty closure of fasciectomy wounds (Dias et al., 2013).  They found that shorter 330 
disease duration, worse preoperative function and longer operation time were 331 
associated with recurrence, though the degree of progression that constituted 332 
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recurrence was not formally defined.  These factors could not be studied with the 333 
cross sectional study design used here. 334 
Others have investigated the factors associated with poor outcome in the absence of 335 
recurrence of disease (Misra et al., 2007), highlighting that ‘poor outcome’ in 336 
Dupuytren’s disease is not entirely due to recurrence. 337 
Recurrence has been the focus of much research in Dupuytren’s disease (Becker 338 
and Davis, 2010).  Whilst treating recurrent disease may be challenging, doing so 339 
following an aponeurotomy may be more straightforward than after more invasive 340 
surgery (van Rijssen and Werker, 2012), and so not all recurrences may have the 341 
same implications regarding future treatment.  Furthermore, recurrence alone cannot 342 
be used as a surrogate for functional outcome, as the correlation between angular 343 
deformity and loss of function is weak (Engstrand et al., 2009, Jerosch-Herold et al., 344 
2011, Zyluk and Jagielski, 2007). 345 
The choice of recurrence as the primary endpoint for studying treatment in 346 
Dupuytren’s disease is challenged by the data presented here, which demonstrates 347 
the different rates of complications after different treatments.  As many of these 348 
complications are not associated with recurrence, they will not be captured if 349 
recurrence is used as the sole outcome measure.  Consequently, recurrence may be 350 
a surgeon-centred outcome, but is less likely to be patient-centred and it may be of 351 
limited value in cost utility analyses. 352 
Functional outcome 353 
After controlling for some independent variables that might differ between the groups 354 
(Table 5), functional outcome was not significantly different between these three 355 
procedures.  This finding requires confirmation in a study with a larger number of 356 
patients treated with dermofasciectomy and aponeurotomy with 5-year follow-up.  357 
This is as complications that limit function, such as loss of flexion, cold intolerance 358 
and altered sensation may be more frequent following more invasive procedures, 359 
which typically had higher complication rates in this study. 360 
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The variables associated with poorer outcome in this study differ from those 361 
identified as contributing to the Dupuytren’s diathesis in other studies (Abe et al., 362 
2004, Hindocha et al., 2006, Hueston, 1963).  This suggests that those patients 363 
whose hand function is worse following surgery may not always be the patients who 364 
experience recurrence. 365 
Several variables were associated with poor function.  Patients undergoing revision 366 
treatment may not achieve as good hand function as those undergoing primary 367 
surgery due to an accumulation of iatrogenic insult to the hand or perhaps due to 368 
disease severity.  Women reported worse hand function than men, though it is not 369 
clear why.  It may be intrinsic to the DASH itself, as similar patterns have been 370 
reported with the QuickDASH in carpal tunnel release (Jenkins et al., 2012).  371 
Diabetics might be expected to have greater risk of complications, such as infection 372 
and poor healing, and so worse rehabilitation.  Alternatively, their higher DASH 373 
scores may reflect a higher prevalence of comorbid upper limb conditions, such as 374 
cheirarthropathy, trigger fingers and carpal tunnel syndrome (Larkin et al., 2014, 375 
Pandey et al., 2013).  Although at least two Dupuytren’s-specific measures 376 
(Beaudreuil et al., 2011, Mohan et al., 2014) exist, the DASH is the most commonly 377 
employed measure to assess the outcome after Dupuytren’s disease surgery (Ball et 378 
al., 2013).  Therefore, the data presented here are important to consider when 379 
interpreting the findings of studies regarding functional outcome in Dupuytren’s 380 
disease. 381 
When the independent variables studied were controlled for, there was no difference 382 
in the odds of having poor hand function 5 years after aponeurotomy compared to 383 
fasciectomy or dermofasciectomy.  This may reflect a greater risk of recurrence after 384 
aponeurotomy being offset by the less invasive nature of the procedure resulting in 385 
less frequent or less severe complications.  However, given the limitations of this 386 
study, a randomised controlled trial with hand function as the primary endpoint is 387 
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required to confirm this and to facilitate comparison of the relative cost effectiveness 388 
of different treatments for Dupuytren’s disease. 389 
 390 
Limitations 391 
The most important limitation to this study relates to its cross-sectional design.  As a 392 
result, the preoperative and immediate postoperative states of patients are not 393 
known and may not have been matched between the three different treatments.  394 
Steps were taken to improve the reliability of the data presented.  Firstly, centres that 395 
contributed had different treatment preferences, with some favouring aponeurotomy 396 
and others fasciectomy.  Secondly, our use of logistic regression analyses 397 
compensated for differences between groups.  Despite this, our comparison between 398 
procedure types is not as robust as one based on the results of a prospective 399 
comparative study.  Nevertheless, our findings for the factors associated with poor 400 
functional outcome are important in their own right, but require verification with a 401 
prospective, preferably randomised, study. 402 
Some of our variables were self-reported and may not have been accurate.  For 403 
example, smoking status may have changed since the patient underwent surgery, 404 
there may have been recall bias and social desirability responses may have 405 
influenced the data with patients denying or underestimating factors such as 406 
excessive alcohol intake or smoking.  Studying such variables prospectively would 407 
be more reliable. 408 
Some sub groups within our study were relatively small and our findings need to be 409 
validated in larger size studies or even with registry-level data.  However, our rates of 410 
complications are largely comparable to those previously reported (Crean et al., 411 
2011).  412 
There are other limitations to our data that might explain why some findings differ 413 
from those of other studies.  There may have been selection bias in our study as we 414 
recruited retrospectively.  There may also be differences in the preoperative states of 415 
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the digits treated in different studies, or in patient or surgeon attitudes.  The latter 416 
may either relate to different cultural norms in different countries or perhaps related 417 
to involvement in a trial compared to routine clinical practice.  However, given the 418 
paucity of literature that focuses primarily on functional outcome in Dupuytren’s 419 
disease, rather than recurrence, we believe that our study is important and should 420 
influence the design of future research studies. 421 
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Table 1: Sample sizes studied 
 1 YEAR FOLLOW UP 5 YEAR FOLLOW UP 
 Numbers of procedures having an 
objective analysis 
Numbers of patients having a 
functional analysis 
Numbers of procedures having an 
objective analysis 
Numbers of patients having a 
functional analysis 
Total 
 
270 245 162 159 
Aponeurotomy 114 104 20 19 
Fasciectomy 126 118 125 124 
Dermofasciectomy 30 23 17 16 
 
Table 2: Patient demographics 
Demographic  
Age (years) Mean 66, Range 33-89 
Men : Women 318 : 95 (77% men) 
Right hand dominance 371/413 (90%) 
Diabetic 61/413 (15%) 
Smoker 60/413 (15%) 
Self reported weekly alcohol intake (UK units/week) 
(1 UK unit = 10 milligrams ethanol) 
Mean 14.7 
Previous ipsilateral surgery prior to index operation 103/413 (25%) 
Index operation was revision of previously treated digit 85/413 (21%) 
Self reported positive family history of Dupuytren’s disease 180/413 (44%) 
Knuckle pads present 122/413 (30%) 
Right hand treated 212/413 (51%) 
Digit studied 248 little (60%) 
129 ring (31%) 
25 middle (6%) 
9 index (2%) 
2 thumb (0.5%) 
 
Table 3: Objective outcomes 
* Due to small numbers in groups, Monte Carlo significances are presented, with 99% confidence intervals in brackets, based on 10 000 
sampled tables 
Outcome  Aponeurotomy Fasciectomy Dermofasciectomy Chi square test  
Numbers of reoperations at: 1 year 5/114 (4.4%) 3/126 (2.4%) 0/30 (0%) p=0.396 (0.384, 0.409)* 
5 years 6/20 (30.0%) 9/126 (7.1%) 0/17 (0%) p=0.003 (0.002, 0.005)* 
      
Objective outcome poor 
(Reoperation or no reoperation 
but either MCPJ or PIPJ>25o 
fixed flexion contracture) 
1 year 25/114 (21.9%) 48/126 (38.1%) 14/30 (46.7%) p=0.006 
5 years 8/20 (40.0%) 61/125 (48.8%) 10/17 (58.8%) p=0.521 
Table 4: Functional outcomes 
*One way ANOVA 
†Chi square test, with Monte Carlo simulation when group frequencies include 5 or fewer (99% confidence intervals in brackets, 10 000 
replicates) 
Outcome Time 
point 
Aponeurotomy Fasciectomy Dermofasciectomy Statistical significance 
between procedures 
DASH summary score 1 year 9.5 (6.8, 12.2) 10.7 (7.6, 13.8) 14.3 (6.2, 22.5) p=0.421* 
(mean (95%CIs)) 
 
5 years 9.1 (4.7, 13.5) 10.9 (8.3, 13.5) 15.1 (5.5, 24.8) p=0.448* 
Proportion of patients 
reporting DASH>15 
1 year 19/104 (18.3%) 26/118 (22.0%) 7/23 (30.4%) p=0.416† 
5 years 5/19 (26.3%) 34/124 (27.4%) 5/16 (31.3%) p=0.952 (0.947, 0.958)† 
Table 5: Logistic regression of function 
 
Independent variable Adjusted 
Odds 
Ratio 
(OR) 
95% confidence 
intervals of 
adjusted OR 
Rank by 
p value 
(i) 
† 
(i/m)*Q 
p value 
threshold 
† 
Significance 
of 
association 
(p value) 
Gender      
 Women 3.88 2.15-6.99 1 0.015 <0.001 
 Men 1     
Previous ipsilateral Dupuytren’s surgery     
 Yes 2.13 1.18-3.85 2 0.031 0.012 
 No 1     
Diabetic      
 Yes 2.07 1.10-3.91 3 0.046 0.025 
 No 1     
Smoker      
 Yes 1.67 0.83-3.37 4 0.062 0.149 
 No 1     
Little finger surgery      
 No 1.34 0.79-2.27 5 0.077 0.268 
 Yes 1     
Length of follow up       
 5 years  1.34 0.79-2.27 6 0.092 0.284 
 1 year 1     
Knuckle pads      
 Present 1.31 0.76-2.28 7 0.108 0.334 
 Absent 1     
Further surgery since material 
operation 
     
 Yes 1.60 0.58-4.43 8 0.123 0.364 
 No 1     
Age at surgery      
 Under 50 years 1.53 0.56-4.16 9 0.138 0.409 
 50 years or over 1     
Procedure was fasciectomy     
 Fasciectomy 1.25 0.68-2.28 10 0.154 0.479 
 Aponeurotomy 1     
Procedure was dermofasciectomy     
 Dermofasciectomy 1.21 0.45-3.27 11 0.169 0.702 
 Aponeurotomy 1     
Family history of Dupuytren’s disease     
 Yes 1.05 0.64-1.74 12 0.184 0.842 
 No 1     
Weekly alcohol intake      
 ≤ 28 units 1.01 0.49-2.08 13  0.981 
 >28 units 1     
 
† - These columns form part of the false discovery rate adjustment to the p value threshold.  The 
variables are ordered by their p value, and ranked (their rank is labelled as ‘i’).  The total number of tests 
(‘m’) is 13.  The false discovery rate that has been tolerated in the analysis (‘Q’) is 20%.  The adjusted p 
value threshold to protect against false discovery for each variable is (i/m)*Q. 
Table 6: Complications 
Complication Time point Aponeurotomy 
(total n=134) 
Fasciectomy 
(total n=251) 
Dermofasciectomy 
(total n=47) 
Significance between 
procedures (Chi square 
tests) 
Reoperation 1 year 5/114 (4.4%) 3/126 (2.4%) 0/30 (0%) 0.396 (0.384, 0.409)* 
5 years 6/20 (30.0%) 8/125 (6.4%) 0/17 (0%) 0.003 (0.002, 0.005)* 
Cold intolerance 1 year 11/114 (9.6%) 39/126 (31.0%) 19/30 (63.3%) <0.001 
5 years 1/20 (5.0%) 20/126 (15.9%) 5/17 (29.4%) 0.140 (0.131, 0.148)* 
Flexion loss>10mm 1 year 20/114 (17.5%) 42/126 (33.3%) 13/30 (43.3%) 0.002 
5 years 3/20 (15.0%) 30/125 (24.0%) 3/17 (17.6%) 0.706 (0.694, 0.718)* 
Altered sensation† 6/134 (4.5%) 38/251 (15.1%) 9/47 (19.1%) 0.003 
Infection 2/134 (1.5%) 22/251 (8.8%) 7/47 (14.9%) 0.004 (0.002, 0.005)* 
CRPS 1/134 (0.7%) 5/251 (2.0%) 0/47 (0%) 0.411 (0.399, 0.424)* 
Statistically significant results are emboldened 
* Due to small numbers in some groups, Monte Carlo significances are presented, with 99% confidence intervals in brackets, based on 10 000 
sampled tables 
† Defined as absent 2 point discrimination at 6 millimetres in either radial or ulnar digital nerve territories over the pulp of the distal phalanx 
Table 7: Significant independent variables in logistic regression analyses of adverse 
outcomes 
Adverse 
outcome 
 
Independent 
variable 
Adjusted 
Odds 
Ratio 
(OR) 
95% confidence 
intervals of 
adjusted OR 
Rank 
by p 
value 
(i) 
† 
(i/m)*Q 
p value 
threshold 
† 
Significance 
of 
association 
(p value)  
Cold intolerance      
 Dermofasciectomy 14.77 5.78-37.74 1 0.02 <0.001 
 Aponeurotomy 1     
      
 Fasciectomy 4.00 1.97-8.12 2 0.04 <0.001 
 Aponeurotomy 1     
      
 Dermofasciectomy 3.69 1.75-7.80 3 0.06 0.001 
 Fasciectomy 1     
       
 1-year follow up 2.68 1.54-4.67 4 0.08 0.001 
 5-year follow up 1     
       
 Smoker 2.66 1.44-4.94 5 0.1 0.002 
 Non-smoker 1     
       
Loss of flexion>10mm      
 Dermofasciectomy 5.34 2.16-13.21 1 0.02 <0.001 
 Aponeurotomy 1     
      
 Fasciectomy 3.66 1.86-7.17 2 0.04 <0.001 
 Aponeurotomy 1     
      
Altered sensation      
 Fasciectomy 3.09 1.21-7.85 1 0.02 0.018 
 Aponeurotomy 1     
     
 Dermofasciectomy 3.91 1.19-12.80 2 0.04 0.024 
 Aponeurotomy 1     
     
 Female 2.11 1.10-4.03 3 0.06 0.024 
 Male 1     
     
Infection     
 Dermofasciectomy 7.59 1.42-43.42 1 0.02 0.018 
 Aponeurotomy 1     
      
 Fasciectomy 6.07 1.33-27.60 2 0.04 0.020 
 Aponeurotomy 1     
      
 Revision 
procedure 
2.36 1.03-5.38 3 0.06 0.041 
 Primary procedure 1     
 
† - These columns form part of the false discovery rate adjustment to the p value threshold.  The 
variables are ordered by their p value, and ranked (their rank is labelled as ‘i’).  The total number of tests 
in each regression model (‘m’) is 10.  The false discovery rate that has been tolerated in the analysis 
(‘Q’) is 20%.  The adjusted p value threshold to protect against false discovery for each variable is 
(i/m)*Q. 
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